GLP-1R多态性修改了孕期糖尿病暴露与后代BMI增长之间的关系:EPOCH研究
Kylie K Harrall1,2,3, Deborah H Glueck4, Leslie A Lange3,5
1Lifecourse Epidemiology of Adiposity and Diabetes Center, University of Colorado Anschutz Medical Campus, Aurora, CO.
孕期糖尿病 (GDM) 暴露会影响儿童的BMI轨迹. 特定的葡萄糖类1受体基因 (GLP-1R) 多态性影响这种关联,影响后代的BMI增长,但不影响葡萄糖-胰岛素恒温标志物.
科学领域:
- 遗传学和发育生物学
- 儿科内分泌学 儿科内分泌学
- 代谢健康 代谢健康
背景情况:
- 孕产妇妊娠糖尿病 (GDM) 与儿童体重指数 (BMI) 的升高有关.
- 葡萄糖类1受体基因 (GLP-1R) 在代谢调节中发挥作用.
- 了解GDM暴露后对后代代谢健康的遗传影响至关重要.
研究的目的:
- 调查特定的GLP-1R基因多态性是否会改变母亲GDM暴露和儿童BMI轨迹之间的关系.
- 为了确定GLP-1R多态性是否会影响葡萄糖-胰岛素恒温的标志物,在暴露于GDM在子宫中的青少年中.
主要方法:
- 对464名参与者进行了分析,这些参与者来自"探索儿童围产期结果 (EPOCH) "研究.
- 在儿童时期进行GLP-1R多态的微阵列基因型定型 (rs10305420,rs1042044,rs6923761).
- 描述BMI轨迹和评估青春期葡萄糖-胰岛素恒温标志物.
主要成果:
- GLP-1R多态 rs10305420和rs1042044改变了GDM-BMI关联;暴露于GDM的小等位基因携带者平均BMI更高.
- 对于rs6923761,GG基因型的GDM暴露个体的平均BMI显著更高.
- 没有GLP-1R多态性改变了GDM暴露与青少年葡萄糖-胰岛素恒温标志物之间的关联.
结论:
- GLP-1R基因多态性在调节母亲GDM对后代BMI增长的影响方面发挥着重要作用.
- 这些遗传变异导致GDM暴露后后代的BMI轨迹异质化.
- 需要进一步的研究来证实这些发现,并阐明潜在的生物机制.
更多相关视频
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
14:40Instrumentation of Near-term Fetal Sheep for Multivariate Chronic Non-anesthetized Recordings
Published on: October 25, 2015
相关概念视频
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Diabetes Mellitus: Type 2 and Gestational
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Biguanides and Glitazones
